Summary
The absorption of digoxin has been investigated in 8 patients before and after successful treatment of severe right heart failure.3H-digoxin 0.1 mg as a solution, and un-labelled digoxin 0.25 mg as a tablet, were given to fasted patients. Blood samples were taken at various time intervals up to 120 hours and urine was collected over the same period. The concentrations of labelled digoxin in plasma and urine were measured in a liquid scintillation counter, unlabelled digoxin was estimated by radioimmunoassay, and various pharmacokinetic parameters were calculated. There was no significant difference in the plasma concentration curves in severe right heart failure and after its successful treatment, nor did any of the calculated pharmacokinetic parameters change significantly. Therefore, inhibition of the absorption of digoxin appears unlikely. In an additional study to estimate absolute bioavailability two different groups of patients in severe right heart failure were given3H-digoxin 0.1 mg or unlabelled digoxin 0.25 mg i. v. and the pharmacokinetic parameters were compared with those from the previous study. The bioavailability of the3H-digoxin solution and of the digoxin tablet were in the same range as values previously published for healthy volunteers, and patients both with and without cardiac failure.
Similar content being viewed by others
References
Lindenbaum, J., Mellow, M. H., Blackstone, M. O., Butler, V. P.: Variation in biologic availability of digoxin from four preparations. New Engl. J. Med.285, 1344–1347 (1971)
Doherty, J. E.: The clinical pharmacology of digitalis glycosides: A review. Am. J. Med. Sci.255, 382–414 (1968)
Gillmann, H.: Resorption von Digitalisglykosiden. Dtsch. Med. Wochenschr.96, 1175 (1971)
Oliver, G. Ch., Taxman, R., Frederickson, R.: Influence of congestive heart failure on digoxin blood levels. Digitalis Symposium. (Ed. O. Stor-Stein) pp. 336–347. Olso; Gyldenal Norsk Forlag, 1973
Greenblatt, D. J., Smith, T. W., Koch-Weser, J.: Bioavailability of drugs: the digoxin dilemma. Clin. Pharmacokinetios1, 36–51 (1976)
Berman, M., Weiss, M. F.: Mathematical Research Branch. Bethesda, Maryland: National Institute of Arthritis and Metabolic Diseases, N. I. H., 1970
Ohnhaus, E. E., Spring, P., Dettli, L.: Eliminationskinetik und Dosierung von Digoxin bei Patienten mit Niereninsuffizienz. Dtsch. Med. Wochenschr.99, 1797–1803 (1974)
Dengler, H. J., Bodem, G., Wirth, K.: Pharmacokinetic and metabolic studies with lanatoside C, α- and β-acethyl-digoxin and digoxin in man. Pharmacology and the future of man. Proc. 5th Int. Congr. Pharmacology, San Francisco 1972, Vol. 3, pp. 112–126 Basel: Karger 1973
Rabkin, S. W., Grupp, G.: A two compartment open model for digoxin pharmacokinetics in patients receiving a wide range of digoxin doses. Acta Cardiol.30, 343–351 (1975)
Reuning, R. H., Sams, R. A., Notari, R. E.: Role of pharmacokinetics in drug dosage adjustment. I. Pharmacologic effect kinetics and apparent volume of distribution. J. Clin. Pharmacol.13, 127–141 (1973)
Nyberg, L., Andersson, K. E., Bertler, A.: Bioavailability of digoxin from tablets. II. Radioimmunoassay and disposition pharmacokinetics of digoxin after intravenous administration. Acta Pharmacol. Suec.2, 459–470 (1974)
Beveridge, T., Nüesch, E., Ohnhaus, E. E.: Absolute bioavailability of digoxin tablets. Arzneim. Forsch. (Drug Res.)28, 701–703 (1978)
Greenblatt, D. J., Duhme, D. W., Koch-Weser, J., Smith, T. W.: Intravenous digoxin as a bioavailability standard: slow infusion and rapid injection. Clin. Pharmacol. Ther.15, 510–513 (1974)
Greenblatt, D. J., Duhme, D. W., Koch-Weser, G., Smith, T. W.: Evaluation of digoxin bioavailability in single-dose studies. New Engl. J. Med.289, 651–654 (1973)
Sanchez, N., Sheiner, L. B., Halking, H., Melmon, K. L.: Pharmacokinetics of digoxin: interpreting bioavailability. Br. Med. J.1973/IV, 132–154
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ohnhaus, E.E., Vozeh, S. & Nuesch, E. Absorption of digoxin in severe right heart failure. Eur J Clin Pharmacol 15, 115–120 (1979). https://doi.org/10.1007/BF00609874
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00609874